Cancer cell: myc失调促进代谢重编程和肿瘤发生还需一因子

2015-02-06 佚名 生物谷

                                 &n

                                                              
近日,著名国际生物学期刊cancer cell在线刊登了美国科学家的一项最新研究成果,他们发现癌基因myc对肿瘤代谢的重编程还需要myc超家族成员mondoA的共同作用。这项研究为抑制肿瘤发生提供了一条新的策略。
 
研究人员指出,当Myc发生功能失调,其能够在转录水平对细胞代谢进行重编程,促进肿瘤形成。Patrick A. Carroll等人发现癌基因myc还需要myc超家族成员,营养感应转录因子mondoA的作用共同促进肿瘤发生。通过对mondoA或与其发生二聚化的mix进行敲低,能够阻断myc诱导的多条代谢途径重编程,导致细胞凋亡发生。再对myc和mondoA共调控的基因进行鉴定和敲低,研究人员发现脂质合成对维持myc驱动的肿瘤存活具有非常重要的作用。通过对临床肿瘤病人研究进一步发现 myc和mondoA共调控基因的过表达与许多癌症病人的不良状况都具有相关性。
 
综上所述,该文章表明,myc和mondoA能够对肿瘤代谢进行共同调节,因此,抑制mondoA及其靶基因或可成为治疗肿瘤的一条有效途径。

原始出处

Carroll PA1, Diolaiti D1, McFerrin L1, Gu H2, Djukovic D2, Du J3, Cheng PF1, Anderson S1, Ulrich M1, Hurley JB4, Raftery D5, Ayer DE6, Eisenman RN7.Deregulated Myc Requires MondoA/Mlx for Metabolic Reprogramming and Tumorigenesis.Cancer Cell. 2015 Jan 28

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869019, encodeId=60401869019c8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jun 22 08:10:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780646, encodeId=735d1e80646c1, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu May 14 05:10:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959270, encodeId=491919592e026, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 11 20:10:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16051, encodeId=f4c41605195, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:33:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274791, encodeId=dd0712e47918d, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 08 00:10:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15251, encodeId=ad711525149, content=基因本无恶,但是联合一起,可能成为恶人, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Feb 07 10:26:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869019, encodeId=60401869019c8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jun 22 08:10:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780646, encodeId=735d1e80646c1, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu May 14 05:10:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959270, encodeId=491919592e026, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 11 20:10:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16051, encodeId=f4c41605195, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:33:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274791, encodeId=dd0712e47918d, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 08 00:10:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15251, encodeId=ad711525149, content=基因本无恶,但是联合一起,可能成为恶人, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Feb 07 10:26:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869019, encodeId=60401869019c8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jun 22 08:10:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780646, encodeId=735d1e80646c1, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu May 14 05:10:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959270, encodeId=491919592e026, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 11 20:10:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16051, encodeId=f4c41605195, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:33:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274791, encodeId=dd0712e47918d, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 08 00:10:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15251, encodeId=ad711525149, content=基因本无恶,但是联合一起,可能成为恶人, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Feb 07 10:26:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-12-11 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869019, encodeId=60401869019c8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jun 22 08:10:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780646, encodeId=735d1e80646c1, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu May 14 05:10:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959270, encodeId=491919592e026, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 11 20:10:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16051, encodeId=f4c41605195, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:33:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274791, encodeId=dd0712e47918d, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 08 00:10:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15251, encodeId=ad711525149, content=基因本无恶,但是联合一起,可能成为恶人, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Feb 07 10:26:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-02-16 Johnny1989

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869019, encodeId=60401869019c8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jun 22 08:10:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780646, encodeId=735d1e80646c1, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu May 14 05:10:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959270, encodeId=491919592e026, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 11 20:10:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16051, encodeId=f4c41605195, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:33:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274791, encodeId=dd0712e47918d, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 08 00:10:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15251, encodeId=ad711525149, content=基因本无恶,但是联合一起,可能成为恶人, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Feb 07 10:26:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-02-08 guihongzh
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869019, encodeId=60401869019c8, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jun 22 08:10:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780646, encodeId=735d1e80646c1, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu May 14 05:10:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959270, encodeId=491919592e026, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 11 20:10:00 CST 2015, time=2015-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16051, encodeId=f4c41605195, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:33:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274791, encodeId=dd0712e47918d, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 08 00:10:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15251, encodeId=ad711525149, content=基因本无恶,但是联合一起,可能成为恶人, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat Feb 07 10:26:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-02-07 medcardio

    基因本无恶,但是联合一起,可能成为恶人

    0

相关资讯

CTG:基因突变或同饮酒吸烟“协作”增加胰腺炎风险

近日,一项发表于国际杂志Clinical and Translational Gastroenterology上的研究论文中,来自匹兹堡大学的研究人员通过研究发现,遗传突变、吸烟以及饮酒可相互作用共同增加个体患慢性胰腺炎的风险,相关研究或可揭示为何某些个体会患慢性胰腺炎,而单独的重度吸烟或重度饮酒者却并无疾病表现。 研究者David Whitcomb解释道,疾病的发病过程开始于急性胰腺炎,炎性症

Nature Communications:监测肿瘤状态的特殊基因

近日,刊登在国际杂志Nature Communications上的一篇研究论文中,来自西奈山医疗中心(Mount Sinai Medical Center)的研究人员通过研究发现两种癌症药物可以开启特殊基因的表达,而这种特殊基因则可以告知肿瘤细胞使其处于休眠状态。 文章中研究者表示,当名为NR2F1的基因开启后其就会重编程肿瘤细胞使其处于休眠状态;而当该基因的表达关闭后肿瘤细胞就会开始分裂并且发

医生必看:高通量基因测序产前筛查与诊断技术规范(试行)

2015年1月15日,卫计委妇幼司发布第一批产前诊断试点单位,同时发布了高通量基因测序产前筛查与诊断技术规范(试行)。与卫计委医政司发布的第一批试点相比,本次妇幼司发布的《通知》更为详细。这份高通量基因测序产前筛查与诊断技术规范(试行)规定了高通量基因测序产前筛查在临床上的适用范围、临床服务流程及临床质量控制。另外,还给出了高通量基因测序产前筛查与诊断知情同意书、临床申请单及临床报告单的参考模

基因诊断行业监管的“小媳妇”现状

基因诊断,又称之为DNA诊断或分子诊断,是应用分子生物学方法,检测患者体内遗传物质结构或表达水平的变化,继而做出诊断的技术,它为疾病的预防、预测、诊断、治疗和疾病转归提供更为准确的信息。有报道称,2014年的全球体外诊断市场达到500亿美元,中国市场为60亿美元左右,其中基因诊断占比10%左右,并将以每年10%~20%的增长幅度连续增长,占体外诊断各类细分市场增长幅度之首。 然而,我国基因诊

Nat Commun:新型乳腺癌基因的重大发现:BCL11A基因活跃在难治的三阴性乳腺癌中

一项新的研究确定了活跃在乳腺癌亚型中的基因。研究表明,过度活化的BCL11A基因驱动着三阴性乳腺癌发展和进程。 在人类细胞和老鼠上的研究为靶向治疗这种侵略性的肿瘤类型提供了新的途径。 有许多类型的乳腺癌对治疗的反应大有不同,也有不同的预测。大约五分之一的患者患有三阴性乳腺癌,这些癌症缺乏三种受体蛋白,而这些蛋白用于其他亚型的乳腺癌的应对激素疗法。近年来已经获得明显研究结果,大多数三阴性肿瘤有基

Nature biotechnology:新发现染色质绝缘子或可用于人类基因治疗

                插入突变和遗传毒性通常代表造血系统肿瘤的恶化,同时也是实现基因治疗前景所面临的最大障碍。George Stamatoyannopoulos等人研究出一种能够识别作为绝缘子发挥功能的紧凑序列元件的方法,或对实现基因